AU2001269927A1 - Thrombomodulin analogs for pharmaceutical use - Google Patents

Thrombomodulin analogs for pharmaceutical use

Info

Publication number
AU2001269927A1
AU2001269927A1 AU2001269927A AU6992701A AU2001269927A1 AU 2001269927 A1 AU2001269927 A1 AU 2001269927A1 AU 2001269927 A AU2001269927 A AU 2001269927A AU 6992701 A AU6992701 A AU 6992701A AU 2001269927 A1 AU2001269927 A1 AU 2001269927A1
Authority
AU
Australia
Prior art keywords
analogs
pharmaceutical use
thrombomodulin
thrombin
thrombomodulin analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269927A
Inventor
David Light
Michael John Morser
Mariko Nagashima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU2001269927A1 publication Critical patent/AU2001269927A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to the design, production and use of analogs of thrombomodulin (TM) that have the ability to enhance the thrombin-mediated activation of protein C but which have a significantly reduced ability to promote activation of thrombin-activatable fibrinolysis inhibitor (TAFI). These analogs are useful in, for example, antithrombotic therapy.
AU2001269927A 2000-06-21 2001-06-20 Thrombomodulin analogs for pharmaceutical use Abandoned AU2001269927A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21367800P 2000-06-21 2000-06-21
US60/213,678 2000-06-21
US09/880,484 2001-06-12
US09/880,484 US6632791B1 (en) 2000-06-21 2001-06-12 Thrombomodulin analogs for pharmaceutical use
PCT/US2001/019590 WO2001098352A2 (en) 2000-06-21 2001-06-20 Thrombomodulin analogs for pharmaceutical use

Publications (1)

Publication Number Publication Date
AU2001269927A1 true AU2001269927A1 (en) 2002-01-02

Family

ID=26908302

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001269927A Abandoned AU2001269927A1 (en) 2000-06-21 2001-06-20 Thrombomodulin analogs for pharmaceutical use

Country Status (10)

Country Link
US (2) US6632791B1 (en)
EP (1) EP1292673B1 (en)
JP (1) JP4855627B2 (en)
AT (1) ATE309339T1 (en)
AU (1) AU2001269927A1 (en)
DE (1) DE60114819T2 (en)
DK (1) DK1292673T3 (en)
ES (1) ES2256266T3 (en)
NO (1) NO20026147L (en)
WO (1) WO2001098352A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118580A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and thrombomodulin polypeptides
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
CA2483909A1 (en) * 2002-05-01 2003-11-13 Schering Aktiengesellschaft Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
US8012693B2 (en) 2003-12-16 2011-09-06 3M Innovative Properties Company Analysis of chemically crosslinked cellular samples
US7833978B2 (en) 2004-02-20 2010-11-16 Emory University Thrombomodulin derivatives and conjugates
CA2625619A1 (en) 2005-10-14 2007-04-26 Medimmune, Inc. Cell display of antibody libraries
EP2120049A1 (en) 2008-05-14 2009-11-18 PAION Deutschland GmbH Soluble thrombomodulin as a biomarker for treatments using anticoagulants
WO2010006635A1 (en) * 2008-07-16 2010-01-21 Paion Deutschland Gmbh Treatment of inflammatory bowel disease
EA201170201A1 (en) * 2008-07-16 2011-08-30 Пайон Дойчланд Гмбх PREVENTION AND TREATMENT OF RADIATION DAMAGE
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
AU2009347614A1 (en) * 2009-06-12 2012-01-19 Paion Deutschland Gmbh Treatment of coagulopathy with hyperfibrinolysis
EP2600891B1 (en) 2010-08-05 2018-01-17 Council of Scientific & Industrial Research Protein fusion constructs possessing thrombolytic and anticoagulant properties
WO2014020183A1 (en) * 2012-08-03 2014-02-06 Ici Immunochemical Intelligence Gmbh In-vitro assay for diagnosis of disorders of haemostasis
US9156904B2 (en) * 2013-07-29 2015-10-13 Blue Blood Biotech Corp. Thrombomodulin variants and use thereof
US11085031B2 (en) * 2016-04-28 2021-08-10 Saint Louis University Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256770A (en) 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
US5466668A (en) 1989-04-28 1995-11-14 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
US6063763A (en) 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
AU4533093A (en) * 1992-06-10 1994-01-04 Michael John Morser Mutants of the epidermal growth factor domains of human thrombomodulin

Also Published As

Publication number Publication date
WO2001098352A3 (en) 2002-08-01
DK1292673T3 (en) 2006-03-27
DE60114819T2 (en) 2006-08-10
ATE309339T1 (en) 2005-11-15
US6632791B1 (en) 2003-10-14
JP4855627B2 (en) 2012-01-18
DE60114819D1 (en) 2005-12-15
EP1292673B1 (en) 2005-11-09
NO20026147D0 (en) 2002-12-20
JP2004527452A (en) 2004-09-09
NO20026147L (en) 2003-02-20
US20030186883A1 (en) 2003-10-02
ES2256266T3 (en) 2006-07-16
US6790828B2 (en) 2004-09-14
WO2001098352A2 (en) 2001-12-27
EP1292673A2 (en) 2003-03-19

Similar Documents

Publication Publication Date Title
AU2001269927A1 (en) Thrombomodulin analogs for pharmaceutical use
GB2340121B (en) Delivery system
AU2001292757A1 (en) Modified selex processes without purified protein
MXPA03001431A (en) Polymorphs of an epothilone analog.
WO2004041153A3 (en) Pharmaceutical composition including low dosages of desmopressin
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
AP1787A (en) Novel perindopril salt and pharmaceutical compositions containing same.
AU2001264515A1 (en) Melphalan derivatives and their use as cancer chemotherapeutic drugs
MXPA03010549A (en) Oxcarbazepine dosage forms.
AU8738401A (en) Novel kallikrein gene
AU2924699A (en) Tryptase inhibitors
IL165988A0 (en) Process for the preparation of fibrinogen
UA86399C2 (en) Normal;heading 1;heading 2;USE OF 2,5-DIHYDROXYBENZENESULPHONIC ACID IN THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF ANGIODEPENDENT DISEASES
AU2125300A (en) Cyclosporin derivatives and method for the production of said derivatives
ZA200208761B (en) Pharmaceutical form of administration for peptides, methods for its production and use.
HK1075013A1 (en) Crystal modification of a cyclic depsipeptide having improved strength
RS83104A (en) Process to prepare eplerenone
HUP0202729A2 (en) Compositions for parenteral use of estramustine phosphate and amino acids
WO2001096366A3 (en) Dipeptide inhibitors for the blood-clotting factor xa
HUP0202592A2 (en) Transdermal delivery of lasofoxifene
IL151647A0 (en) Novel lhrh-antagonists, production and use thereof as medicament
UA83989C2 (en) Isolated peptide for promoting anti-tumor immune response, pharmaceutical composition based thereon and use thereof
HUP0301523A2 (en) Vegf peptides and their use for inhibiting angiogenesis
GB0221169D0 (en) Crystal
WO2003022883A3 (en) Use of proteins for the production of a medicament for stimulating the innate non specific immune system